Diabetic Macular Edema Video Perspectives

Rishi P. Singh, MD

Singh reports consulting for Alcon, Apellis, Genentech, Novartis and Regeneron.
February 01, 2023
1 min watch
Save

VIDEO: Managing treatment burden in DME

Transcript

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

You know, treatment burden is the first conversation I have with a lot of patients when I first meet them. I talk about how we're going to get to know each other very well over the next year or two because of the fact that they're going to have very frequent visits. And the vast majority of studies, when you look at 5 years out, have shown less frequent visits over time with intensive therapy for the first 2 years. If we can get past the first 2 years, and I know pretty much that that number of injections goes way down and potentially there'll be less burden on the patient, albeit that those first 2 years are pretty burdensome.